

Study Number: C13114-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

Study Number:

Study Sex:

PWG Approval Date:

Version:

Stat Version:

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)-4-tert-butylphenol

CAS Number: 3147-76-0

C13114-01

Male

See web page for date of PWG Approval

v1.2.4

2.1.1A

Date Report Requested: 06/15/2021

Time Report Requested: 08:27:45

Lab: Battelle

Study Number: C13114-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)-4-tert-butylphenol

CAS Number: 3147-76-0

Date Report Requested: 06/15/2021

Time Report Requested: 08:27:45

Lab: Battelle

		Male							
		Treatment Groups (mg/kg)							
	Phase Day	0		30		100		300	
Hematocrit (%)	SD 14	49.3	± 1.3 (5)	51.0	± 0.9 (5)	50.9	± 0.6 (5)	49.6	± 1.2 (5)
Percent of Control				103.4		103.2		100.6	
Manual Hematocrit (%)	SD 14	48.4	± 0.7 (5) *	50.6	± 1.0 (5)	50.4	± 0.7 (5)	48.2	± 0.5 (5)
Percent of Control				104.5		104.1		99.6	
Hemoglobin (g/dL)	SD 14	15.2	± 0.3 (5) *	16.1	± 0.2 (5)	15.8	± 0.2 (5)	15.3	± 0.2 (5)
Percent of Control				105.5		103.7		100.7	
Erythrocytes (10 ⁶ /uL)	SD 14	8.60	± 0.20 (5)	8.97	± 0.18 (5)	8.86	± 0.05 (5)	8.58	± 0.20 (5)
Percent of Control				104.3		103.0		99.8	
Reticulocytes (10 ³ /uL)	SD 14	244.3	± 52.2 (5) *	218.2	± 9.4 (5)	246.0	± 2.9 (5)	264.6	± 10.3 (5)
Percent of Control				89.3		100.7		108.3	
Mean Cell Volume (fL)	SD 14	57.3	± 0.6 (5)	56.9	± 0.5 (5)	57.4	± 0.7 (5)	57.8	± 0.7 (5)
Percent of Control				99.2		100.2		100.8	
Mean Cell Hemoglobin (pg)	SD 14	17.7	± 0.2 (5)	17.9	± 0.2 (5)	17.8	± 0.2 (5)	17.9	± 0.2 (5)
Percent of Control				101.1		100.7		100.8	
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	30.9	± 0.2 (5)	31.5	± 0.2 (5)	31.1	± 0.2 (5)	30.9	± 0.4 (5)
Percent of Control				102.1		100.6		100.1	
Platelets (10 ³ /uL)	SD 14	862	± 48 (5) **	802	± 22 (5)	717	± 19 (5)	809	± 58 (5)
Percent of Control				92.9		83.1		93.8	
White Blood Cells (10 ³ /uL)	SD 14	12.31	± 1.25 (5)	13.27	± 0.40 (5)	12.80	± 0.57 (5)	13.65	± 1.08 (5)
Percent of Control				107.8		104.0		110.9	
Neutrophils (10 ³ /uL)	SD 14	1.19	± 0.31 (5) *	1.26	± 0.09 (5)	1.37	± 0.07 (5)	1.49	± 0.10 (5)
Percent of Control				106.2		115.3		125.0	

Study Number: C13114-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)-4-tert-butylphenol

CAS Number: 3147-76-0

Date Report Requested: 06/15/2021

Time Report Requested: 08:27:45

Lab: Battelle

Male

		Treatment Groups (mg/kg)			
	Phase Day	0	30	100	300
Lymphocytes (10 ³ /uL)	SD 14	10.47 ± 0.78 (5)	11.31 ± 0.31 (5)	10.63 ± 0.51 (5)	11.51 ± 0.89 (5)
Percent of Control			107.9	101.5	109.9
Monocytes (10 ³ /uL)	SD 14	0.38 ± 0.11 (5)	0.42 ± 0.05 (5)	0.53 ± 0.01 (5)	0.38 ± 0.07 (5)
Percent of Control			111.6	139.5	100.0
Basophils (10 ³ /uL)	SD 14	0.06 ± 0.01 (5)	0.07 ± 0.01 (5)	0.05 ± 0.01 (5)	0.06 ± 0.01 (5)
Percent of Control			120.7	93.1	110.3
Eosinophils (10 ³ /uL)	SD 14	0.07 ± 0.02 (5)	0.10 ± 0.02 (5)	0.09 ± 0.01 (5)	0.11 ± 0.02 (5)
Percent of Control			148.6	122.9	154.3
Large Unstained Cells (10 ³ /uL)	SD 14	0.14 ± 0.06 (5)	0.11 ± 0.01 (5)	0.13 ± 0.02 (5)	0.11 ± 0.02 (5)
Percent of Control			77.5	94.4	77.5

Study Number: C13114-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)-4-tert-butylphenol

CAS Number: 3147-76-0

Date Report Requested: 06/15/2021

Time Report Requested: 08:27:45

Lab: Battelle

Male

	Phase Day	Treatment Groups	
		1000	
Hematocrit (%)	SD 14	47.4 ± 0.7	(5)
Percent of Control		96.2	
Manual Hematocrit (%)	SD 14	46.2 ± 0.4	(5)
Percent of Control		95.5	
Hemoglobin (g/dL)	SD 14	14.6 ± 0.1	(5)
Percent of Control		96.1	
Erythrocytes (10 ⁶ /uL)	SD 14	8.24 ± 0.09	(5)
Percent of Control		95.8	
Reticulocytes (10 ³ /uL)	SD 14	322.2 ± 30.2	(5)
Percent of Control		131.9	
Mean Cell Volume (fL)	SD 14	57.6 ± 0.7	(5)
Percent of Control		100.4	
Mean Cell Hemoglobin (pg)	SD 14	17.7 ± 0.2	(5)
Percent of Control		100.0	
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	30.8 ± 0.2	(5)
Percent of Control		99.8	
Platelets (10 ³ /uL)	SD 14	685 ± 58	(5) **
Percent of Control		79.5	
White Blood Cells (10 ³ /uL)	SD 14	14.12 ± 0.95	(5)
Percent of Control		114.7	
Neutrophils (10 ³ /uL)	SD 14	2.72 ± 1.08	(5)
Percent of Control		228.6	

Study Number: C13114-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)-4-tert-butylphenol

CAS Number: 3147-76-0

Date Report Requested: 06/15/2021

Time Report Requested: 08:27:45

Lab: Battelle

Male

	Phase Day	Treatment Groups
		1000
Lymphocytes (10 ³ /uL)	SD 14	10.63 ± 0.58 (5)
Percent of Control		101.5
Monocytes (10 ³ /uL)	SD 14	0.46 ± 0.04 (5)
Percent of Control		120.0
Basophils (10 ³ /uL)	SD 14	0.06 ± 0.01 (5)
Percent of Control		103.4
Eosinophils (10 ³ /uL)	SD 14	0.13 ± 0.02 (5)
Percent of Control		191.4
Large Unstained Cells (10 ³ /uL)	SD 14	0.11 ± 0.00 (5)
Percent of Control		76.1

Study Number: C13114-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)-4-tert-butylphenol

CAS Number: 3147-76-0

Date Report Requested: 06/15/2021

Time Report Requested: 08:27:45

Lab: Battelle

LEGEND

Values given as mean $\pm$ SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis were performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

**** END OF REPORT ****